The present disclosure provides a method and system for estimating the clinical responsiveness of a patient to a dose of a plasminogen activating agent to treat a thrombosis, comprising determining a concentration of α2-antiplasmin in a blood sample of the patient, determining a concentration of activated fibrinolysis inhibitor (“TAFI”) in the blood sample, determining a concentration of plasminogen activator Inhibitor 1 (“PAI-1”) in the blood sample, computing a clot lysis time (“CLT”) based on the concentrations of a2-antiplasmin, TAFI and PAI-1 using the equation CLT=−2,813.6+31.1*a2-antiplasmin (percent activity)+31.1*TAFI (percent activity)+1.49 PAI-1 (ug/L), and determining that the patient is at increased risk of hemorrhage when the computed CLT is less than a first predetermined cutoff time.

The inventors produced substances that neutralize the activity of a bispecific antibody having an activity of functionally substituting for FVIII, and undertook the construction of methods for measuring the reactivity of FVIII that can ensure accuracy even in the presence of this bispecific antibody. As a result, the inventors discovered that in APTT-based one-stage clotting assay, FVIII activity in the plasma of a hemophilia A patient can be evaluated accurately, and also that in APTT-based Bethesda assay, FVIII inhibitor titer in the plasma of a hemophilia A patient carrying a FVIII inhibitor can be evaluated accurately.

The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A. In some embodiments, the present disclosure provides methods for dosing a hemophilia A patient with a polynucleotide, e.g., a codon-altered polynucleotide, encoding a Factor VIII polypeptide.

Devices and methods for determining activity of one or more coagulation factors in a blood sample are provided. The device may comprise an inlet port for deposition of a sample, a reaction compartment, a detection compartment, a control compartment, or any combination thereof. One or more compartments may be fluidically connected. One or more compartments may comprise plasma deficient of a coagulation factor, an ionic citrate source, an ionic calcium source, one or more coagulation contact phase activator reagents, a phospholipid, or a mixture, or any combination thereof.

Disclosed are an immunochemical assay device and a method of using the immunochemical assay device for detecting one or more targets or markers such as Cardiac Troponin I, NT-pro-BNP, D-dimer and/or cross-linked fibrin in a fluid sample.

A medical analyzer and coagulation profiler performs various interrogations on specimens. A motor with reduction gearing moves and a video camera observes the samples, the cartridges or parts thereof. Changes in images are compared and recorded with a central processor that controls a display. Power supply, temperature controller, motor and gearing are mounted in a box which attaches to a smartphone. The smartphone provides the video camera, illumination and central processor that control the movement, temperature and display. The device makes testing simpler for small hospitals, clinics, ambulances, remote locations and individuals and controls a number of parallel or serial devices operating simultaneously or sequentially. A cartridge insertion actuates a circular motion to generate a blood profile based on changes. Change is analyzed with a video camera and processor such as in a smartphone and is plotted to show an amplitude and time. A smartphone provides a specific movement pattern.

The present invention relates to a method for diagnosing anomalies in the coagulation of blood, comprising the following successive steps: a) placing a sample of total blood in a holder containing two pairs of electrodes connected to an apparatus generating an electrical current; b) incubating this sample for 60 to 180 seconds in the presence of calcium; c) adding to this sample tissue factor in a concentration high enough to trigger the coagulation of the blood; d) measuring the impedance variation between the electrodes as a function of time, for a period comprised between 10 and 30 minutes from step (c), and generating a curve of the impedance values as a function of time; e) comparing the value of the area under the curve generated in step (d) with the value of an area under a reference curve.

Provided herein are compositions, systems, and methods for monitoring platelet activation. In particular, provided herein are sensor devices for measuring platelet activation and uses thereof.

Provided are novel human-derived antibodies specific for Fibroblast Activation Protein (FAP), preferably capable of selectively inhibiting the enzymatic activity of FAP, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with FAP are provided. Assays and kits related to antibodies specific for FAP are also disclosed. The novel anti-FAP antibodies can be used in pharmaceutical and diagnostic compositions for FAP-targeted immunotherapy and diagnostics.

The present invention provides a method of detecting platelet activation in a patient, the method comprising the steps of a) obtaining a blood sample from a patient suspected of having heparin-induced thrombocytopenia (HIT); b) incubating an effective amount of platelet factor 4 (PF4) with a sample of platelets to yield a sample of PF4-treated platelets; c) contacting the patient blood sample with the PF4-treated platelets; and d) measuring the extent of platelet activation, wherein an increase in platelet activation compared with results obtained using a normal blood sample is indicative of the patient having HIT.